Literature DB >> 10973942

Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity.

Y Imai1, M Soda, R Takahashi.   

Abstract

Autosomal recessive juvenile parkinsonism (AR-JP) is caused by mutations in the parkin gene. Parkin protein is characterized by a ubiquitin-like domain at its NH(2)-terminus and two RING finger motifs and an IBR (in between RING fingers) at its COOH terminus (RING-IBR-RING). Here, we show that Parkin is a RING-type E3 ubiquitin-protein ligase which binds to E2 ubiquitin-conjugating enzymes, including UbcH7 and UbcH8, through its RING-IBR-RING motif. Moreover, we found that unfolded protein stress induces up-regulation of both the mRNA and protein level of Parkin. Furthermore, overexpression of Parkin, but not a set of mutants without the E3 activity, specifically suppressed unfolded protein stress-induced cell death. These findings demonstrate that Parkin is an E3 enzyme and suggest that it is involved in the ubiquitination pathway for misfolded proteins derived from endoplasmic reticulum and contributes to protection from neurotoxicity induced by unfolded protein stresses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10973942     DOI: 10.1074/jbc.C000447200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  223 in total

1.  Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death.

Authors:  L Stefanis; K E Larsen; H J Rideout; D Sulzer; L A Greene
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

Review 2.  Orchestrating the unfolded protein response in health and disease.

Authors:  Randal J Kaufman
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 3.  Programmed cell death and new discoveries in the genetics of parkinsonism.

Authors:  Robert E Burke
Journal:  J Neurochem       Date:  2007-12-10       Impact factor: 5.372

4.  Human resistin, a proinflammatory cytokine, shows chaperone-like activity.

Authors:  Madhuri Suragani; Varma D Aadinarayana; Aleem Basha Pinjari; Karunakar Tanneeru; Lalitha Guruprasad; Sharmistha Banerjee; Saurabh Pandey; Tapan K Chaudhuri; Nasreen Zafar Ehtesham
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-26       Impact factor: 11.205

5.  Structure of human ubiquitin-conjugating enzyme E2 G2 (UBE2G2/UBC7).

Authors:  Ryoichi Arai; Seiko Yoshikawa; Kazutaka Murayama; Yuzuru Imai; Ryosuke Takahashi; Mikako Shirouzu; Shigeyuki Yokoyama
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-03-25

Review 6.  The genetics of Parkinson's disease.

Authors:  Kah Leong Lim; Valina L Dawson; Ted M Dawson
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

7.  Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants.

Authors:  Jessica C Greene; Alexander J Whitworth; Isabella Kuo; Laurie A Andrews; Mel B Feany; Leo J Pallanck
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

8.  Interferon-inducible ubiquitin E2, Ubc8, is a conjugating enzyme for protein ISGylation.

Authors:  Keun Il Kim; Nadia V Giannakopoulos; Herbert W Virgin; Dong-Er Zhang
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

9.  The Spen homolog Msx2-interacting nuclear target protein interacts with the E2 ubiquitin-conjugating enzyme UbcH8.

Authors:  Junfeng Li; Jishu Wang; Xi Yang; Junlin Li; Hongyan Qin; Xiao Dong; Yangting Zhu; Liang Liang; Yingmin Liang; Hua Han
Journal:  Mol Cell Biochem       Date:  2006-04-01       Impact factor: 3.396

10.  Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.

Authors:  Christophe Lo Bianco; Bernard L Schneider; Matthias Bauer; Ali Sajadi; Alexis Brice; Takeshi Iwatsubo; Patrick Aebischer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.